Berta Biltz

Berta Biltz serves as a procurement specialist focused on advanced life sciences and pharmaceutical development, overseeing the acquisition of complex research, development, and manufacturing capabilities for critical health-related technologies. Her work supports the end-to-end lifecycle of biopharmaceutical products, from early-stage scientific research to scaled production, ensuring alignment with federal health and safety standards. She manages competitive solicitations under full and open competition, coordinating with technical evaluators and program managers to define performance requirements and ensure compliance with regulatory frameworks such as cGMP and FDA guidelines. Biltz engages with a diverse pool of vendors specializing in pharmaceutical formulation, biological product synthesis, and life sciences R&D. While no single contractor dominates her portfolio, she consistently collaborates with mid-to-large-scale manufacturers and contract research organizations possessing validated GMP facilities, analytical testing capabilities, and experience in aseptic processing. Her contracting approach emphasizes technical qualification, supply chain resilience, and regulatory readiness over sole-source reliance. Biltz’s procurement activity is entirely under full and open competition, with no set-asides applied to her acquisitions. This reflects a strategic focus on accessing specialized technical expertise and large-scale manufacturing capacity that may not be available within small business categories, rather than a lack of commitment to socioeconomic programs. Her approach prioritizes mission-critical performance and scientific rigor over socioeconomic preferences. Her primary procurement focus lies in NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 325414 (Biological Product Manufacturing), with significant activity in NAICS 541712 for life sciences R&D services. She procures clinical-grade active pharmaceutical ingredients, biologics production systems, and preclinical development services, demonstrating deep familiarity with process validation, stability testing, and regulatory submission support. Her expertise centers on the intersection of scientific innovation and compliant manufacturing in the biopharmaceutical sector.